US Markets
Home›US Markets›Equities›Zai Lab Advances Atopic Dermatitis Candidate Toward Po…
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis. Strong Biomarker Inhibition And Extended Half-Life Data from 48 healthy volunteers showed that ZL-1503 rapidly and sustainably blocked the IL-13 pathway. A single dose of 200 mg or higher inhibited phosphorylated STAT6, a key atopic dermatitis signaling biomarker, by at least 90% through Week 12. The treatment also lowered circulating type 2 inflammatory biomarkers,
Latest closeNasdaq Comp. 25,366.09 ▼0.4%
← Newer storyEli Lilly Breaks Ground on $3.5B Lehigh Valley Manufacturing CampusOlder story →Is a bottom in for the Nasdaq-100? Charts to watch